TransMedics gets US trial OK for organ care system
This article was originally published in Clinica
Executive Summary
Edging closer to a worldwide $1bn market, TransMedics has received IDE approval from the US FDA to begin the pilot phase of clinical trials for its Organ Care system (OCS), which preserves donor organs in a "living" state outside of the body. The PROCEED trial will evaluate the safety and performance of the OCS in 20 patients, from five centres across the US: the University of Pittsburgh Medical Center, UCLA Medical Center, The Cleveland Clinic, The University of Chicago Medical Center and Brigham & Women's Hospital.
You may also be interested in...
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.